Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Expenses for 3 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 20.06% to $21.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $89.8 million, a 32.99% increase, with the full-year FY2025 number at $89.8 million, up 32.99% from a year prior.
  • Operating Expenses was $21.9 million for Q4 2025 at Artiva Biotherapeutics, down from $22.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $22.9 million in Q3 2025 to a low of $3.2 million in Q4 2023.
  • A 3-year average of $17.4 million and a median of $18.3 million in 2024 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 476.79% in 2024; the steepest drop was 5.67% in 2024.
  • Artiva Biotherapeutics' Operating Expenses stood at $3.2 million in 2023, then soared by 476.79% to $18.3 million in 2024, then increased by 20.06% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Operating Expenses are $21.9 million (Q4 2025), $22.9 million (Q3 2025), and $22.8 million (Q2 2025).